High-dose Docetaxel with Granulocyte Colony-stimulating Factor for Mobilization of Autologous Peripheral Blood Stem/Progenitor Cells in Patients with Malignant Solid Tumors

Objective The efficacy of high-dose therapy(HDT) with peripheral blood progenitor cell(PBPC) transplantation for patients with solid tumors remains undefined.An important prerequisite for this mode of therapy is a reliable methord of obtaining sufficient PBPCs to ensure rapid and durable engraftment while maintaining patients in at least a stable disease state at the time of commencing the high-dose phase of therapy.Docetaxel has an effective anti-tumour activity in mang solid tumors.The objective of our study is to explore the efficacy and safety of high2dose of docetaxel with granulocyte colony2stimulating factor ( G2CSF) for mobilization of peripheral blood stem cells. Methods 　The 30 patient s with malignant solid tumors were involved in our study. Docetaxel (120 mg/ m2 ) was given with a continuous int ravenous infusion for 3 hours on day 1. When the number of white blood cell was reached to 1. 0 ×109 / L, G2CSF 5μg/ kg was given twice a day by injection subcutaneous until the end of leukopheresis. Results 　The leukopheresis was started on average day 9. 97 ±1. 03 following docetaxel therapy, the mean number of CD34 + cells was 3. 49 ×106 / kg ( range 1. 71 ×106 / kg～16. 69 ×106 / kg), by two times per patient of leukopheresis. There are 25 cases whose number of CD34 + cells is more than 2. 0 ×106 / kg. The average day is (6. 47 ±1. 01) when the number of white blood cells was reduced to 1. 0 ×109 / L af ter docetaxel was given. The average duration is (3. 50 ±1. 01) days for G2CSF injection subcutaneous. No significant difference in number of CD34 + cells was found in different leukopheresis time. 6 cases had mild arthralgia, 3 cases had slight diarrhea, 1 cases had oropharyngeal mucositis. Conclusion 　Docetaxel (120 mg/m2 ) with G2CSF(5μg/ kg) is an effective and safety mobilizing regimen for autologous peripheral blood stem progenitor cells in patient s with malignant solid tumors.